<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120895">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01749371</url>
  </required_header>
  <id_info>
    <org_study_id>12-189</org_study_id>
    <nct_id>NCT01749371</nct_id>
  </id_info>
  <brief_title>Vitamin E Supplementation in Burned Patients</brief_title>
  <official_title>Vitamin E Supplementation in Burned Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shriners Hospitals for Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Hermann Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas, Galveston</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A dietary antioxidant, alpha-tocopherol, will be used to potentially attenuate Vitamin E
      short- and long-term losses in plasma and adipose, reverse the oxidative stress of burn
      injury and, in the process, decrease the secondary consequences of burn injury, including
      lung injury and impaired wound healing.  This may improve the quality of life of the burn
      patient by preventing pathophysiology that may result from oxidative stress and may reduce
      hospital stay. Our research will lay the foundation for the future development of effective,
      safe, and economic therapeutic interventions to treat burn injury-associated metabolic
      abnormalities.  Also, it will provide the basis for the development of supplemental
      regulations and pharmacotherapy to treat burn patients with vitamin E.  The risks are very
      reasonable in relation to the anticipated benefits to our subjects because a) vitamin E is a
      simple vitamin that is abundant and approved for clinical use, and b) the subjects will be
      monitored consistently for the minimal increased tendency to bleed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Plasma Alpha- and Gamma-Tocopherol</measure>
    <time_frame>Days 0-30</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function Testing</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Stress Test</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound Healing</measure>
    <time_frame>Days 0-30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and Urine Malondialdehyde, Isoprostanes, Vitamin E Metabolites</measure>
    <time_frame>Days 0-30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose Alpha- and Gamma-Tocopherol</measure>
    <time_frame>Days 0-30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Burn</condition>
  <arm_group>
    <arm_group_label>Early Vitamin E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin E is administered from Days 1-15 after the initial excision surgery after admission.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed Vitamin E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin E is administered from Days 16-30 after the initial excision surgery after admission.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin E (dl-Alpha Tocopheryl)</intervention_name>
    <arm_group_label>Early Vitamin E</arm_group_label>
    <arm_group_label>Delayed Vitamin E</arm_group_label>
    <other_name>Vitamin E</other_name>
    <other_name>dl-Alpha Tocopheryl</other_name>
    <other_name>Alpha Tocopherol</other_name>
    <other_name>Aqueous Vitamin E Oral Drops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 16 - 85 years

          -  â‰¥40% total body surface area burn

        Exclusion Criteria:

          -  Septic shock

          -  Bleeding disorders

          -  Diabetes, or on diabetes medications or anti-lipidemic agents

          -  Arthritis

          -  Known kidney/renal disease, endocrine disease, cancer, heart disease, osteoporosis,
             liver disease

          -  Congestive heart failure

          -  Positive hepatitis or HIV screens

          -  Pregnancy (women)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Perenlei Enkhbaatar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda E Sousse, PhD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linda E Sousse, PhD, MBA</last_name>
    <phone>3617285536</phone>
    <email>lesousse@utmb.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Perenlei Enkhbaatar, MD, PhD</last_name>
    <phone>4097470096</phone>
    <email>peenkhba@utmb.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center, Parkland Health and Hospital System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven E Wolf, MD</last_name>
      <phone>214-648-2041</phone>
      <email>steven.wolf@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Agnes Burris, RN</last_name>
      <phone>2146483521</phone>
      <email>agnes.burris@utsouthwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steven Wolf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Hunt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brett Arnoldo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch: Blocker Burn Unit and Shriners Hospitals for Children</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perenlei Enkhbaatar, MD, PhD</last_name>
      <phone>409-747-0096</phone>
      <email>peenkhba@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Linda E Sousse, PhD, MBA</last_name>
      <phone>3617285536</phone>
      <email>lesousse@utmb.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Perenlei Enkhbaatar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hal K Hawkins, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jong O Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda E Sousse, PhD, MBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David N Herndon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristofer Jennings, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Celeste C Finnerty, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronald P Mlcak, PhD, MBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital Burn Intensive Care Unit</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James M Cross, MD</last_name>
      <phone>713-500-6407</phone>
      <email>James.M.Cross@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jeanette M Podbielski, RN</last_name>
      <phone>7135006407</phone>
      <email>Jeanette.M.Podbielski@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James M Cross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd Huzar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Wade, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 20, 2013</lastchanged_date>
  <firstreceived_date>December 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alpha-Tocopherol</keyword>
  <keyword>Gamma-Tocopherol</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Malondialdehyde</keyword>
  <keyword>Isoprostanes</keyword>
  <keyword>Lung Dysfunction</keyword>
  <keyword>Wound Healing</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Alpha-Tocopherol</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
